Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

A Phase I/II Trial of Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

Isatuximab targets and kills CD38-positive myeloma cells in manner similar to rituximab's mechanism of action on CD20-positive lymphoma cells. Based on the synergy between rituximab and bendamustine, as well as the established clinical efficacy of bendamustine and isatuximab as single agents for multiple myeloma, the logical next step is to combine isatuximab with bendamustine and prednisone. Due to lack of effective therapies in refractory multiple myeloma, herein the investigators propose studying this novel combination in this population, in order to address a significant unmet need. The aim of the investigators is to first determine the maximal tolerated dose of the combination in participants with relapsed/refractory myeloma and then to establish the efficacy of this novel combination.

Study Overview

• Status: Terminated
• Conditions: Multiple Myeloma
• Intervention / Treatment: Biological: Isatuximab; Drug: Bendamustine; Drug: Prednisone

• Study Type: Interventional
• Enrollment (Actual): 15
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Washington University School of Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Diagnosis of multiple myeloma with a measurable disease parameter at time of screening. A measurable disease parameter is defined as one or more of the following:

  • Serum monoclonal protein ≥ 0.5 g/dL
  • 24 hour urine monoclonal protein ≥ 200 mg/24 hour
  • Serum free light chain ratio > 5x normal ratio with an absolute difference of 10mg/dL between the involved and uninvolved free light chain
  • Soft tissue plasmacytoma ≥ 2 cm measurable by either physical examination and/or applicable radiographs (e.g. MRI, CT, etc.)
  • Bone marrow plasma cells ≥ 30%

• Triple-class-refractory disease defined as both of the following:

  • Previously received treatment with a proteasome inhibitor, an immunomodulatory drug, and daratumumab, in combination or as single-agents.
  • Refractory (defined per IMWG Consensus Criteria as disease that is nonresponsive while on therapy, or progresses within 60 days of last dose) to most recent therapy.
• At least 6 weeks from the last treatment with daratumumab to the first study treatment
• At least 18 years of age.
• Performance status of ECOG ≤ 2 Note: Participants with lower performance status based solely on bone pain secondary to multiple myeloma will be eligible.

• Normal bone marrow and organ function as defined as ALL of the following:

  • Absolute neutrophil count ≥ 1500/mm3
  • Platelets ≥ 75,000/mm^3 (transfusions not permitted within 7 days of screening)
  • ALT (SGPT) and AST (SGOT) < 3.5 x the upper limit of the institutional normal value (ULN).
  • Total bilirubin ≤ 2.0 x mg/dL.
  • Creatinine clearance > 30 ml/min using Cockcroft-Gault formula
• Females of childbearing potential (FCBP) must agree to refrain from becoming pregnant while on study drug and for 3 months after discontinuation from study drug, and must agree to use adequate contraception including hormonal contraception, (e.g. birth control pills, etc.), barrier method contraception (e.g. condoms), or abstinence during that time frame. Men engaging in sexual intercourse with a FCBP must agree to use adequate contraception including hormonal contraception, (e.g. birth control pills, etc), barrier method contraception (e.g. condoms), or abstinence while on study drug and for 3 months after discontinuation from study drug
• Ability to understand and willing to sign a written informed consent document.

Exclusion Criteria:

• Prior exposure to isatuximab or bendamustine
• History of plasma cell leukemia or MM CNS involvement.
• Receiving renal replacement therapy, hemodialysis, or peritoneal dialysis.
• Diagnosed with another concurrent malignancy requiring treatment.
• Active hepatitis A, B, or C.
• Known intolerance to infused protein products, sucrose, histidine, polysorbate 80 or known hypersensitivity to any of the components of study therapy.
• Receiving any other investigational agents within 14 days prior to enrollment.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
• Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
• Patients with HIV are eligible unless their CD4+ T-cell counts are < 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Phase I Dose Level 1: Isatuximab + Bendamustine + Prednisone; -Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (50 mg/m^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.	Biological: Isatuximab; Isatuximab will be administered on a 28-day cycle; Drug: Bendamustine; Bendamustine will be administered on a 28-day cycle as follows; Other Names: Treanda; Bendeka; Drug: Prednisone; Prednisone will be administered on a 28-day cycle as follows; Other Names: Deltasone; Prednisone Intensol; Rayos
Experimental: Phase I Dose Level 2: Isatuximab + Bendamustine + Prednisone; -Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (75 mg/m^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.	Biological: Isatuximab; Isatuximab will be administered on a 28-day cycle; Drug: Bendamustine; Bendamustine will be administered on a 28-day cycle as follows; Other Names: Treanda; Bendeka; Drug: Prednisone; Prednisone will be administered on a 28-day cycle as follows; Other Names: Deltasone; Prednisone Intensol; Rayos
Experimental: Phase I Dose Level 3: Isatuximab + Bendamustine + Prednisone; -Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (100 mg/m^2) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.	Biological: Isatuximab; Isatuximab will be administered on a 28-day cycle; Drug: Bendamustine; Bendamustine will be administered on a 28-day cycle as follows; Other Names: Treanda; Bendeka; Drug: Prednisone; Prednisone will be administered on a 28-day cycle as follows; Other Names: Deltasone; Prednisone Intensol; Rayos
Experimental: Phase II: Isatuximab + Bendamustine + Prednisone; -Isatuximab (10 mg/kg) on Days 1, 8, 15, and 22 during Cycle 1 and on Days 1 and 15 of subsequent cycles. Bendamustine (dose determined in Phase I portion of study) will be administered on Days 1 and 2 and prednisone (60 mg) will be administered on Days 1 through 4 of each cycle.	Biological: Isatuximab; Isatuximab will be administered on a 28-day cycle; Drug: Bendamustine; Bendamustine will be administered on a 28-day cycle as follows; Other Names: Treanda; Bendeka; Drug: Prednisone; Prednisone will be administered on a 28-day cycle as follows; Other Names: Deltasone; Prednisone Intensol; Rayos

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of regimen (Phase I only)	The maximum tolerated dose (MTD) is defined as the dose level immediately below the dose level at which 2 participants of a cohort (of 2 to 6 participants) experience dose limiting toxicity (DLT) during the first cycle of treatment. Dose escalation will proceed until the MTD has been reached or until the maximum dose of each drug is tested (Dose Level 3). If no more than 1 DLT is observed at dose levels 1, 2 and 3, level 3 will be declared the recommended phase II dose (RP2D) and the MTD will remain undefined.	Completion of first cycle of treatment for all participants enrolled in Phase I portion (estimated to be 9 months)
Overall response rate (ORR) (Phase II only)	-ORR defined as the proportion of patients meeting the criteria for partial response, very good partial response, complete response, or stringent complete response per IMWG 2016 response criteria.	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of adverse events experienced by participants (Phase I and Phase II)	Participants will be evaluated for toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (NCI) version 5.0.	From start of treatment through 30 days after completion of treatment or initiation of new anti-myeloma therapy, whichever occurs first (estimated to be 7 months)
Progression-free survival (PFS) (Phase II only)	Progression-free survival (PFS) will be defined as time from Cycle 1 Day 1 to disease progression or relapse. Any patient who expires, withdraws, or is lost to follow-up prior to disease progression or relapse will be censored at last follow-up. Patients who are removed from study therapy prior to progression or relapse will be censored at the time of initiation of subsequent anti-myeloma treatment.	Up to 5 years after removal from study (estimated to be 5 years and 6 months)
Overall survival (OS) (Phase II only)	Overall survival (OS) will be defined as time from Cycle 1 Day 1 to death due to any causes. Patients who are alive at the time of data analyses will be censored on the last known alive date. Patients who are removed from study therapy prior death will be censored at the time of initiation of subsequent anti-myeloma treatment.	Up to 5 years after removal from study (estimated to be 5 years and 6 months)

Collaborators and Investigators

• Sponsor: Washington University School of Medicine
• Collaborators: Sanofi
• Investigators: Principal Investigator: Ravi Vij, M.D., Washington University School of Medicine

Publications and helpful links

Helpful Links

• Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Study record dates

Study Major Dates

• Study Start (Actual): April 3, 2020
• Primary Completion (Actual): March 13, 2023
• Study Completion (Actual): March 7, 2024

Study Registration Dates

• First Submitted: September 6, 2019
• First Submitted That Met QC Criteria: September 6, 2019
• First Posted (Actual): September 10, 2019

Study Record Updates

• Last Update Posted (Actual): March 19, 2024
• Last Update Submitted That Met QC Criteria: March 17, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Immunoproliferative Disorders; Hematologic Diseases; Hemorrhagic Disorders; Hemostatic Disorders; Paraproteinemias; Blood Protein Disorders; Multiple Myeloma; Neoplasms, Plasma Cell; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Inflammatory Agents; Antineoplastic Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Alkylating; Alkylating Agents; Bendamustine Hydrochloride; Prednisone
• Other Study ID Numbers: 201910194

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes